Ceftriaxone

DRUG INFORMATION

  ADULT
    - ( 2.1 ) Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose
      Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult
      Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not
      exceed 4 g Patients with hepatic impairment and significant renal impairment
      should not receive more than 2 grams per day of ceftriaxone.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage
      and administration', retrieved 2026-08-29
    - Table 1: Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose
      Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult
      Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not
      exceed 4 g Patients with hepatic impairment and significant renal impairment
      should not receive more than 2 grams per day of ceftriaxone.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for ceftriaxone (CEFTRIAXONE
      AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29

  CHILD
    - Ceftriaxone for Injection and Dextrose Injection in the DUPLEX® Container is
      designed to deliver a 1 g or 2 g dose of ceftriaxone. To prevent unintentional
      overdose, this product should not be used in pediatric patients who require less
      than the full 1 g or 2 g adult dose of ceftriaxone.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section
      'pediatric use', retrieved 2026-08-29
    - To prevent unintentional overdose, this product should not be used in pediatric
      patients who require less than the full 1 g or 2 g adult dose of ceftriaxone.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section
      'pediatric use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - ( 2.1 ) Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose
      Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult
      Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not
      exceed 4 g Patients with hepatic impairment and significant renal impairment
      should not receive more than 2 grams per day of ceftriaxone.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage
      and administration', retrieved 2026-08-29
    - Table 1: Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose
      Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult
      Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not
      exceed 4 g Patients with hepatic impairment and significant renal impairment
      should not receive more than 2 grams per day of ceftriaxone.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for ceftriaxone (CEFTRIAXONE
      AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29
    - Hepatic and renal impairment Patients with both hepatic and renal impairment
      should not receive more than 2 grams of ceftriaxone per day ( 5.8 ) Pediatric
      Patients Ceftriaxone for Injection and Dextrose Injection in the DUPLEX® Container
      is designed to deliver a 1 g or 2 g dose of ceftriaxone.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in
      specific populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - ( 2.1 ) Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose
      Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult
      Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not
      exceed 4 g Patients with hepatic impairment and significant renal impairment
      should not receive more than 2 grams per day of ceftriaxone.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage
      and administration', retrieved 2026-08-29
    - Table 1: Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose
      Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult
      Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not
      exceed 4 g Patients with hepatic impairment and significant renal impairment
      should not receive more than 2 grams per day of ceftriaxone.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for ceftriaxone (CEFTRIAXONE
      AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29
    - The pharmacokinetics of ceftriaxone were only minimally altered in geriatric
      patients compared to healthy adult subjects and dosage adjustments are not
      necessary for geriatric patients with ceftriaxone dosages up to 2 grams per day,
      provided there is no severe renal and hepatic impairment. [see Clinical
      Pharmacology (12) ]
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in
      specific populations', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Available data from published prospective cohort studies, case
      series, and case reports over several decades with cephalosporin use, including
      Ceftriaxone, in pregnant women have not established a drug-associated risk of
      major birth defects, miscarriage, or adverse maternal or fetal outcomes.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section
      'pregnancy', retrieved 2026-08-29
    - In animal reproduction studies, no adverse developmental effects were observed
      when ceftriaxone was administered to pregnant rats at doses up to approximately
      2.8 times the clinical dose of 2 g/day (see Data) .
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section
      'pregnancy', retrieved 2026-08-29
    - The estimated background risk of major birth defects and miscarriage for the
      indicated population is unknown.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - No adverse effects were noted on various reproductive parameters during gestation
      and lactation, including postnatal growth, functional behavior, and reproductive
      ability of the offspring. 8.2 Lactation Risk Summary Data from published
      literature report that ceftriaxone is present in human milk.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in
      specific populations', retrieved 2026-08-29
    - There are no data on the effects of Ceftriaxone on the breastfed child or on milk
      production.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in
      specific populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for Ceftriaxone for Injection and Dextrose
      Injection and any potential adverse effects on the breastfed child from
      Ceftriaxone for Injection and Dextrose Injection or from the mother’s underlying
      condition.
      Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in
      specific populations', retrieved 2026-08-29